Maria 01, Building 5
Lapinlahdenkatu 16, 00180 Helsinki
Making history? email@example.com
Press inquiries: firstname.lastname@example.org
Cardiac diseases and related premature deaths are the top burden in health care globally – 49 million people suffer from heart diseases in Europe alone. CardioSignal, a smartphone app approved as a medical device, helps detect atrial fibrillation, making monitoring heart health more accessible to people.
CardioSignal is a brand and a product by Precordior, a Finnish health technology company.The solution measures micro-motions of the chest using the accelerometer and gyroscope which can already be found from most smartphones. The non-invasive, cloud-based automated analysis of motion data provides a new way for general practitioners (GPs) to accurately assess heart-atrial fibrillation (AFib). The company aims to expand the capabilities to other heart diseases in the future.
What makes our position unique is our capability to harness the everyday device, smartphone, to detect severe heart diseases accurately.
Juuso Blomster Cardiologist & CEO of CardioSignal.
Detecting serious heart issues early can save a life. CardioSignal’s technology is patented and clinically tested to detect atrial fibrillation with 96% accuracy. CardioSignal is an academic spinoff that is based on a decade of research and algorithm development. The company focuses on scientific research and collaborates with several universities and hospitals on clinical studies and trials for other heart disease applications.
Cardiosignals CEO Juuso Blomster (Ph.D. MD Cardiologist) holds a Specialist in Cardiology degree and is an Adjunct Professor in Cardiology at the University of Turku, Finland. Prior to CardioSignal, he’s held several international positions in the medical and pharmaceutical industries. Mikko Pänkäälä is the company’s CSO and has 8+ years experience in cardiac measurement technology. Tero-Pekka Alastalo is the Chief Medical Officer and General Manager for US operations.
Precordior has over 30 patents in the area of heart motion monitoring methods, and CardioSignal has been approved for atrial fibrillation detection as a CE-certified class IIa medical device in Europe, with ambitions to expand to United States in the future.
Detecting serious heart issues early can save lives. The CardioSignal solution and the company’s focus on scientific research and collaborations with several universities have impressed us. They are well positioned to fundamentally change the way heart diseases are being diagnosed.
Ilkka Kivimäki Founding partner at Maki.vc.